Optinose Inc (OPTN) has issued an announcement.
OptiNose, Inc. has announced the FDA’s approval of its drug XHANCE for treating chronic rhinosinusitis in adults, a significant milestone for those tracking the pharmaceutical sector. Following this approval, the company is now tasked with conducting a study on the drug’s effects in children aged 12 to 17, with a deadline to initiate the study by the end of 2024 and complete it by early 2028, ensuring XHANCE’s safety and efficacy across a broader age range. This development could impact OptiNose’s market position and investor interest.
For a thorough assessment of OPTN stock, go to TipRanks’ Stock Analysis page.
